Telix Completes Acquisition of Next-Gen Therapeutic Assets and Innovative Biologics Technology Platform February 4, 2025
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Ph 3 Trial of ANKTIVA and PD-1 Checkpoint Inhibitor Combination in NSCLC February 4, 2025
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals February 4, 2025
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development February 4, 2025
FIRCE-1 Ph 2 Study of Firi-cel to Discontinue; Advances Remaining Programs While Evaluating Strategic Options February 4, 2025
Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study of sirexatamab (DKN-01) Reported February 4, 2025
Positive Topline Results of Ph 3 COMPETE Trial with ITM-11 in Patients with Gr 1 or 2 GEP-NETs announced February 4, 2025
Positive interim Alpha DaRT data from multiple clinical trials in pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other clinical trials announced February 4, 2025
Positive topline results from the OS analysis of the Ph 3 INAVO120 study of Itovebi + Ibrance & fulvestrant for people with PIK3CA-mut HR+ve, HER2-neg endocrine-resistant, locally advanced or metastatic breast cancer announced February 4, 2025
Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer February 4, 2025
NMPA approves Sarclisa + SOC VRd in China for patients with newly diagnosed multiple myeloma ineligible for transplant February 4, 2025
